Vectibix (panitumumab) - Rare cases of Stevens-Johnson syndrome and Toxic Epidermal Necrolysis

Amgen Canada Inc., in consultation with Health Canada, would like to inform you of important updates to safety information regarding the risk of Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) associated with the use of Vectibix®. Vectibix is indicated as monotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Read more here.